Essential Thrombocythemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
In essential thrombocythemia, there is mainly an overproduction of platelet-forming cells in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech, and transient ischemic attacks.
The Essential Thrombocythemia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Thrombocythemia (Oncology) and features dormant and discontinued projects.
Essential Thrombocythemia Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Essential Thrombocythemia pipeline drugs market are Histone Deacetylase 1, Histone Deacetylase 2, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Programmed Cell Death 1 Ligand 1, Tyrosine Protein Kinase JAK2, Apoptosis Regulator Bcl 2, Arginase 1, Bcl 2 Like Protein 1, and Bcl 2 Like Protein 2.
Essential Thrombocythemia Pipeline Drugs Market Analysis, by Targets
For more Essential Thrombocythemia pipeline drugs market target insights, download a free report sample
Essential Thrombocythemia Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanism of actions of the Essential Thrombocythemia pipeline drugs market are Histone Deacetylase 1 Inhibitor, Histone Deacetylase 2 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Tyrosine Protein Kinase JAK2 Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, Bcl 2 Like Protein 1 Inhibitor, Bcl 2 Like Protein 2 Inhibitor, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and Histone Deacetylase 4 Inhibitor.
Essential Thrombocythemia Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Essential Thrombocythemia pipeline drugs market, download a free report sample
Essential Thrombocythemia Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Essential Thrombocythemia pipeline drugs market are oral, subcutaneous, intravenous, intradermal, intramuscular, and parenteral.
Essential Thrombocythemia Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Essential Thrombocythemia pipeline drugs market, download a free report sample
Essential Thrombocythemia Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Essential Thrombocythemia pipeline drugs market are small molecule, subunit vaccine, recombinant protein, monoclonal antibody, and recombinant vector vaccine.
Essential Thrombocythemia Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Essential Thrombocythemia pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Essential Thrombocythemia pipeline drugs market are IO Biotech Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Imago BioSciences Inc, Innovent Biologics Inc, Italfarmaco SpA, Johnson & Johnson, MEI Pharma Inc, Millennium Pharmaceuticals Inc, and PharmaEssentia Corp.
Essential Thrombocythemia Pipeline Drugs Market Analysis, by Companies
To know more about the Essential Thrombocythemia pipeline drugs market companies, download a free report sample
Essential Thrombocythemia Pipeline Drugs Market Report Overview
Key Targets | Histone Deacetylase 1, Histone Deacetylase 2, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Programmed Cell Death 1 Ligand 1, Tyrosine Protein Kinase JAK2, Apoptosis Regulator Bcl 2, Arginase 1, Bcl 2 Like Protein 1, and Bcl 2 Like Protein 2 |
Key Mechanism of Actions | Histone Deacetylase 1 Inhibitor, Histone Deacetylase 2 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Tyrosine Protein Kinase JAK2 Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, Bcl 2 Like Protein 1 Inhibitor, Bcl 2 Like Protein 2 Inhibitor, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and Histone Deacetylase 4 Inhibitor |
Key Routes of Administration | Oral, Subcutaneous, Intravenous, Intradermal, Intramuscular, and Parenteral |
Key Molecule Types | Small Molecule, Subunit Vaccine, Recombinant Protein, Monoclonal Antibody, and Recombinant Vector Vaccine |
Key Companies | IO Biotech Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Imago BioSciences Inc, Innovent Biologics Inc, Italfarmaco SpA, Johnson & Johnson, MEI Pharma Inc, Millennium Pharmaceuticals Inc, and PharmaEssentia Corp |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
- Reviews of pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
- Evaluation of Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
F. Hoffmann-La Roche Ltd
Imago BioSciences Inc
Innovent Biologics Inc
IO Biotech Inc
Italfarmaco SpA
Johnson & Johnson
MEI Pharma Inc
Millennium Pharmaceuticals Inc
PharmaEssentia Corp
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Sino Biopharmaceutical Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Essential Thrombocythemia pipeline drugs market?
Some of the key targets of the Essential Thrombocythemia pipeline drugs market are Histone Deacetylase 1, Histone Deacetylase 2, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Programmed Cell Death 1 Ligand 1, Tyrosine Protein Kinase JAK2, Apoptosis Regulator Bcl 2, Arginase 1, Bcl 2 Like Protein 1, and Bcl 2 Like Protein 2.
-
What are the key mechanism of actions of the Essential Thrombocythemia pipeline drugs market?
Some of the key mechanism of actions of the Essential Thrombocythemia pipeline drugs market are Histone Deacetylase 1 Inhibitor, Histone Deacetylase 2 Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Tyrosine Protein Kinase JAK2 Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, Bcl 2 Like Protein 1 Inhibitor, Bcl 2 Like Protein 2 Inhibitor, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and Histone Deacetylase 4 Inhibitor.
-
What are the key routes of administration in the Essential Thrombocythemia pipeline drugs market?
The key routes of administration in the Essential Thrombocythemia pipeline drugs market are oral, subcutaneous, intravenous, intradermal, intramuscular, and parenteral.
-
What are the key molecule types in the Essential Thrombocythemia pipeline drugs market?
The molecule types in the Essential Thrombocythemia pipeline drugs market are small molecule, subunit vaccine, recombinant protein, monoclonal antibody, and recombinant vector vaccine.
-
Which are the key companies in the Essential Thrombocythemia pipeline drugs market?
Some of the key companies in the Essential Thrombocythemia pipeline drugs market are IO Biotech Inc, AbbVie Inc, F. Hoffmann-La Roche Ltd, Imago BioSciences Inc, Innovent Biologics Inc, Italfarmaco SpA, Johnson & Johnson, MEI Pharma Inc, Millennium Pharmaceuticals Inc, and PharmaEssentia Corp.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.